Prostate Cancer
The impact of genomic biomarkers on a clinical risk prediction model for upgrading/upstaging among men with favorable-risk prostate cancer.
January 29, 2024
Interactive training workshop to improve prostate mpMRI knowledge: results from the ESOR Nicholas Gourtsoyiannis teaching fellowship.
January 26, 2024
Functional Outcomes After Localized Prostate Cancer Treatment.
January 26, 2024
Impact of PSMA PET on Prostate Cancer Management.
January 26, 2024
Meta-Analysis Evaluating the Impact of Site of Metastasis on Overall Survival in Men With Castration-Resistant Prostate Cancer.
January 26, 2024
Risk stratification of prostate cancer with MRI and prostate-specific antigen density-based tool for personalized decision making.
January 25, 2024
Effect of Concomitant Medications on Treatment Response and Survival in De Novo Metastatic Prostate Cancer: Secondary Analysis of the LATITUDE Study.
January 25, 2024
Physician Perception of Grade Group 1 Prostate Cancer.
January 25, 2024
First-in-human study of PSMA-targeting agent, [18F]AlF-P16-093: dosimetry and initial evaluation in prostate cancer patients.
January 24, 2024
UCHL1 is a potential molecular indicator and therapeutic target for neuroendocrine carcinomas.
January 24, 2024
Divergent immune microenvironments in two tumor nodules from a patient with mismatch repair-deficient prostate cancer.
January 24, 2024